JPH11511360A - 薬物送達および鑑視適用のためのヒト皮膚の微細穿孔 - Google Patents
薬物送達および鑑視適用のためのヒト皮膚の微細穿孔Info
- Publication number
- JPH11511360A JPH11511360A JP9510552A JP51055297A JPH11511360A JP H11511360 A JPH11511360 A JP H11511360A JP 9510552 A JP9510552 A JP 9510552A JP 51055297 A JP51055297 A JP 51055297A JP H11511360 A JPH11511360 A JP H11511360A
- Authority
- JP
- Japan
- Prior art keywords
- stratum corneum
- skin
- selected area
- temperature
- wire
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000012377 drug delivery Methods 0.000 title description 8
- 230000000007 visual effect Effects 0.000 title description 8
- 210000000434 stratum corneum Anatomy 0.000 claims abstract description 272
- 210000003491 skin Anatomy 0.000 claims abstract description 226
- 238000000034 method Methods 0.000 claims abstract description 225
- 239000000126 substance Substances 0.000 claims abstract description 75
- 239000003623 enhancer Substances 0.000 claims abstract description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 55
- 239000012530 fluid Substances 0.000 claims abstract description 35
- 238000010438 heat treatment Methods 0.000 claims abstract description 27
- 238000002679 ablation Methods 0.000 claims abstract description 23
- 238000010521 absorption reaction Methods 0.000 claims abstract description 22
- 230000035699 permeability Effects 0.000 claims abstract description 11
- 230000005611 electricity Effects 0.000 claims abstract description 6
- 210000001519 tissue Anatomy 0.000 claims description 110
- 239000008103 glucose Substances 0.000 claims description 89
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 88
- 210000003722 extracellular fluid Anatomy 0.000 claims description 82
- 230000004907 flux Effects 0.000 claims description 65
- 239000008280 blood Substances 0.000 claims description 54
- 210000004369 blood Anatomy 0.000 claims description 53
- 239000012491 analyte Substances 0.000 claims description 48
- 210000002615 epidermis Anatomy 0.000 claims description 46
- 230000006378 damage Effects 0.000 claims description 30
- 238000001816 cooling Methods 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 29
- 230000035515 penetration Effects 0.000 claims description 28
- 230000008569 process Effects 0.000 claims description 23
- 230000004888 barrier function Effects 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 19
- 230000003287 optical effect Effects 0.000 claims description 18
- 230000001965 increasing effect Effects 0.000 claims description 17
- 238000012544 monitoring process Methods 0.000 claims description 15
- 230000008859 change Effects 0.000 claims description 14
- 238000001704 evaporation Methods 0.000 claims description 13
- 229910052751 metal Inorganic materials 0.000 claims description 13
- 239000002184 metal Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- 238000011084 recovery Methods 0.000 claims description 12
- 230000002708 enhancing effect Effects 0.000 claims description 11
- 239000011148 porous material Substances 0.000 claims description 11
- 238000009835 boiling Methods 0.000 claims description 10
- 238000012546 transfer Methods 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 7
- 230000005284 excitation Effects 0.000 claims description 7
- 230000001678 irradiating effect Effects 0.000 claims description 6
- 102000011782 Keratins Human genes 0.000 claims description 4
- 108010076876 Keratins Proteins 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000012466 permeate Substances 0.000 claims description 4
- 239000004366 Glucose oxidase Substances 0.000 claims description 3
- 108010015776 Glucose oxidase Proteins 0.000 claims description 3
- 229940116332 glucose oxidase Drugs 0.000 claims description 3
- 235000019420 glucose oxidase Nutrition 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 2
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 claims 1
- 238000007398 colorimetric assay Methods 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 230000007480 spreading Effects 0.000 claims 1
- 239000000975 dye Substances 0.000 abstract description 58
- 239000003814 drug Substances 0.000 abstract description 51
- 229940079593 drug Drugs 0.000 abstract description 50
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 239000012141 concentrate Substances 0.000 abstract description 2
- 230000003628 erosive effect Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 73
- 210000004027 cell Anatomy 0.000 description 67
- 239000010410 layer Substances 0.000 description 55
- 150000001875 compounds Chemical class 0.000 description 47
- RBTKNAXYKSUFRK-UHFFFAOYSA-N heliogen blue Chemical compound [Cu].[N-]1C2=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=NC([N-]1)=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=N2 RBTKNAXYKSUFRK-UHFFFAOYSA-N 0.000 description 37
- 238000012360 testing method Methods 0.000 description 28
- 239000000243 solution Substances 0.000 description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
- 238000002604 ultrasonography Methods 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 238000004088 simulation Methods 0.000 description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 239000000049 pigment Substances 0.000 description 18
- 238000009792 diffusion process Methods 0.000 description 14
- 238000009826 distribution Methods 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 13
- 239000012153 distilled water Substances 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- 210000004207 dermis Anatomy 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- 238000005553 drilling Methods 0.000 description 12
- 239000000835 fiber Substances 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 230000008020 evaporation Effects 0.000 description 10
- 231100000862 numbness Toxicity 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 230000033001 locomotion Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000035807 sensation Effects 0.000 description 9
- 230000000699 topical effect Effects 0.000 description 9
- 230000032258 transport Effects 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 8
- 238000002271 resection Methods 0.000 description 8
- 230000037317 transdermal delivery Effects 0.000 description 8
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 210000002510 keratinocyte Anatomy 0.000 description 7
- 229960004194 lidocaine Drugs 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 7
- 229960000907 methylthioninium chloride Drugs 0.000 description 7
- 230000008447 perception Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- -1 but not limited to Chemical compound 0.000 description 6
- 239000000356 contaminant Substances 0.000 description 6
- 210000003811 finger Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 210000000245 forearm Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003961 penetration enhancing agent Substances 0.000 description 5
- 231100000245 skin permeability Toxicity 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000013271 transdermal drug delivery Methods 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 229910002056 binary alloy Inorganic materials 0.000 description 4
- 150000002009 diols Chemical class 0.000 description 4
- 210000001339 epidermal cell Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000000976 ink Substances 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 230000031700 light absorption Effects 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000002123 temporal effect Effects 0.000 description 4
- 210000003813 thumb Anatomy 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002390 adhesive tape Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000020828 fasting Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 3
- 229960004657 indocyanine green Drugs 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000002357 osmotic agent Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000002207 thermal evaporation Methods 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 238000009834 vaporization Methods 0.000 description 3
- 230000008016 vaporization Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- XCJYREBRNVKWGJ-UHFFFAOYSA-N copper(II) phthalocyanine Chemical compound [Cu+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 XCJYREBRNVKWGJ-UHFFFAOYSA-N 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000624 ear auricle Anatomy 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000000608 laser ablation Methods 0.000 description 2
- 150000002632 lipids Chemical group 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000037324 pain perception Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- VVOPUZNLRVJDJQ-UHFFFAOYSA-N phthalocyanine copper Chemical compound [Cu].C12=CC=CC=C2C(N=C2NC(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2N1 VVOPUZNLRVJDJQ-UHFFFAOYSA-N 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- WDQFELCEOPFLCZ-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrolidin-2-one Chemical compound OCCN1CCCC1=O WDQFELCEOPFLCZ-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical group CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 241000427324 Glinus Species 0.000 description 1
- 108091092889 HOTTIP Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001553014 Myrsine salicina Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- CPGKMLVTFNUAHL-UHFFFAOYSA-N [Ca].[Ca] Chemical compound [Ca].[Ca] CPGKMLVTFNUAHL-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940124347 antiarthritic drug Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940005486 antimigraine preparations Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- CEJANLKHJMMNQB-UHFFFAOYSA-M cryptocyanin Chemical compound [I-].C12=CC=CC=C2N(CC)C=CC1=CC=CC1=CC=[N+](CC)C2=CC=CC=C12 CEJANLKHJMMNQB-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- HJXPPCPJEYUQFQ-HNNXBMFYSA-N dodecyl (2s)-5-oxopyrrolidine-2-carboxylate Chemical compound CCCCCCCCCCCCOC(=O)[C@@H]1CCC(=O)N1 HJXPPCPJEYUQFQ-HNNXBMFYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- QCUPYFTWJOZAOB-HYXAFXHYSA-N ectylurea Chemical compound CC\C(=C\C)C(=O)NC(N)=O QCUPYFTWJOZAOB-HYXAFXHYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000081 effect on glucose Effects 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 125000000373 fatty alcohol group Chemical group 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 239000010520 ghee Substances 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000008776 intercellular pathway Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 150000002642 lithium compounds Chemical class 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 150000004291 polyenes Chemical group 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000003304 psychophysiological effect Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
- A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
- A61B5/14514—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/32—Surgical cutting instruments
- A61B17/3203—Fluid jet cutting instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
- A61B18/203—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser applying laser energy to the outside of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00137—Details of operation mode
- A61B2017/00154—Details of operation mode pulsed
- A61B2017/00172—Pulse trains, bursts, intermittent continuous operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00743—Type of operation; Specification of treatment sites
- A61B2017/00747—Dermatology
- A61B2017/00761—Removing layer of skin tissue, e.g. wrinkles, scars or cancerous tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00743—Type of operation; Specification of treatment sites
- A61B2017/00747—Dermatology
- A61B2017/00765—Decreasing the barrier function of skin tissue by radiated energy, e.g. using ultrasound, using laser for skin perforation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00452—Skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00452—Skin
- A61B2018/0047—Upper parts of the skin, e.g. skin peeling or treatment of wrinkles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Optics & Photonics (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Surgical Instruments (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Laser Surgery Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.個体の身体中の分析物の濃度を鑑視するための方法であって、該個体の身体 表面の選択された領域の角質層の該分析物に対する浸透性を増強する工程を包含 し、該工程が、 (a)該選択された領域の角質層を、下にある組織に重大な損傷を起こさずに 該角質層に微細孔を形成し、それによって該分析物の回収に対する該角質層の障 壁特性を減少する手段により穿孔する工程; (b)選択された量の該分析物を回収する工程;および (c)該回収された分析物を定量する工程 を包含する、方法。 2.音波エネルギーを約5kHzから100MHzの範囲の周波数で前記穿孔された選択 領域に適用する工程をさらに包含する請求項1に記載の方法であって、ここで該 音波エネルギーが、周波数変調、振幅変調、位相変調、およびこれらの組合せか らなる群より選択されるメンバーにより変調される、方法。 3.分析物回収をさらに増強するために、前記音波エネルギーの適用とともに、 前記個体の身体の選択された領域を、化学的増強剤と接触させる工程をさらに包 含する、請求項2に記載の方法。 4.前記選択された領域における前記角質層の前記穿孔する工程が、(a)該角 質層の約1000μmまでを横切る選択された領域を、熱供給源と、該選択された領 域中の組織に結合した水および他の気化し得る物質の温度が、該水および他の気 化し得る物質の沸点を超えて上昇し、それによって該選択された領域中の該角質 層を除去するように接触させることにより該角質層を切除する工程;(b)該角 質層を、直径約1000μmまでの微細孔を形成するように較正された微小ランセッ トで穿孔する工程;(c)該角質層を、密接に焦点を合わせた音波エネルギーの ビームを該角質層上に焦点を合わせることにより切除する工程;(d)流体の高 圧ジェットで該角質層を水動力学的に穿孔し、直径約1000μmまでの微細孔を形 成する工程、および(e)電気短パルスで該角質層を穿孔し、直径約1000μmまで の微細孔を形成する工程、からなる群より選択される手段により達成される、請 求項1、2、3、または4に記載の方法。 5.前記穿孔する工程が、前記角質層の約1000μmまでを横切る選択された領域 を、熱供給源と、該選択された領域中の組織に結合した水および他の気化し得る 物質の温度が、該水および他の気化し得る物質の沸点を超えて上昇し、それによ って該選択された領域中の角質層を除去するように接触させることにより達成さ れる、請求項4に記載の方法。 6.少なくとも前記選択された領域を、パルス化光供給源の発光範囲にわたって 強い吸収を示す有効量の色素で処理する工程、および該パルス化光供給源からの 一連のパルス出力を、該色素上に焦点を合わせ、該色素が十分に加熱され熱を該 角質層に伝導により移し、該選択された領域中の組織に結合した水および他の気 化し得る物質の該温度を該水および他の気化し得る物質の沸点を超えて上昇させ る工程を包含する請求項5に記載の方法であって、該色素が熱供給源として機能 する、方法。 7.前記パルス化光供給源が皮膚により有意に吸収されない波長で発光する、請 求項6に記載の方法。 8.前記パルス化光供給源が約630から1550nmの範囲で発光するレーザーダイオ ードである、請求項7に記載の方法。 9.前記パルス化光供給源が、約700nmと3000nmの範囲で発光する、光学パラメ トリックスの発振器で駆動されるレーザーダイオードである、請求項7に記載の 方法。 10.前記パルス化光供給源が、アークランプ、白熱電球、および発光ダイオー ドからなる群から選択されるメンバーである、請求項6に記載の方法。 11.前記角質層の障壁特性が克服されたときを決定するための感知システムを 提供する工程をさらに包含する、請求項6に記載の方法。 12.前記感知システムが、前記選択された領域から反射された光を受け取りそ して発光ダイオード上に該反射された光の焦点を合わせる光収集手段、該焦点を 合わせた光を受け取りそしてコントローラーに信号を送る発光ダイオードであっ て、該シグナルが該反射された光の質を示す、光ダイオード、および該信号を受 け取りそして予め選択されたシグナルが受け取られると該パルス化光供給源を遮 断するための、該発光ダイオードと該パルス化光供給源に接続されたコントロー ラーとを備える、請求項11に記載の方法。 13.前記角質層の選択された領域および隣接する皮膚組織を、穿孔の前に、該 選択された領域および隣接する皮膚組織が、選択された予め冷却された定常状態 条件にあるように冷却手段で冷却する工程をさらに包含する、請求項6に記載の 方法。 14.前記冷却手段がペルチェデバイスを備える、請求項13に記載の方法。 15.前記切除が間質液の滲出を生じ、そして前記分析物が選択された量の該間 質液中に回収される、請求項6に記載の方法。 16.前記選択された量の間質液が回収された後、前記パルス化光供給源からの 有効量のエネルギーを、該微細孔中に残存する間質液を凝固するように適用する ことにより前記微細孔を塞ぐ工程をさらに包含する、請求項15に記載の方法。 17.間質液の滲出を増強するために、前記角質層の穿孔された選択領域に真空 を適用する工程をさらに包含する、請求項15に記載の方法。 18.前記角質層を穿孔する前に、少なくとも前記選択された領域を、前記パル ス化光供給源からの焦点の合わせていない光で、該光で照射された該選択された 領域が滅菌されるように照射する工程をさらに包含する、請求項6に記載の方法 。 19.前記選択された領域を金属ワイヤと接触させる工程を包含する請求項5に 記載の方法であって、該金属ワイヤが熱供給源として、該選択された領域の温度 が周辺の皮膚温度から100℃を超えるまで約10〜50ms以内に上昇され、次いで該 選択された領域の温度がほぼ周辺の皮膚温度にまで約30〜50ms以内に戻るように 機能し、そして温度を上昇することおよび周辺の皮膚温度に戻すことのサイクル を該角質層の障壁特性を減少させるために有効な回数繰り返す工程を包含する、 方法。 20.前記ほぼ周辺の皮膚温度まで戻すことが、前記ワイヤを前記角質層との接 触から引き離すことにより行われる、請求項19に記載の方法。 21.前記ワイヤと前記個体の身体との間の電気的インピーダンスを前記角質層 の選択された領域および隣接皮膚組織を通して監視するための手段、および前記 切除が抵抗の減少と同時に起こるように該ワイヤの位置を進行させるための手段 であって、該ワイヤの加熱の間に該ワイヤが該角質層と接触するように該ワイヤ を進行させる、手段、を提供する工程をさらに包含する、請求項20に記載の方 法。 22.前記ワイヤを前記角質層との接触から引き離すための手段をさらに包含す る請求項21に記載の方法であって、前記鑑視手段が、該角質層の下にある表皮 層との接触に関連するインピーダンスの変化を検出し得、そして該ワイヤを該角 質層との接触から離れるための信号を該引き離すための手段に送り得る、方法。 23.前記金属ワイヤがオーム加熱要素により加熱される、請求項20に記載の 方法。 24.前記金属ワイヤが、高い抵抗点を有する電流ループを含み、そして該高い 抵抗点の温度が、変調された電流を該電流ループを通して通過させることにより 変調されるように形成される、請求項20に記載の方法。 25.前記金属ワイヤが、励起コイルの変調可能な交流磁場に、該励起コイルに 交流を通電することが内部の抵抗損失により該ワイヤを加熱するに十分な渦電流 を発生させるように配置される、請求項20に記載の方法。 26.前記穿孔が、直径約1000μmまでの微細孔を形成するように較正された微 小ランセットで前記角質層を穿孔することにより達成される、請求項4に記載の 方法。 27.前記穿孔が、密接に焦点を合わせた音波エネルギーのビームを前記角質層 上に焦点を合わせることによって該角質層を切除することにより達成される、請 求項4に記載の方法。 28.前記穿孔が、流体の高圧ジェットを用いて水動力学的に前記角質層を穿孔 することにより達成され、直径約1000μmまでの微細孔を形成する、請求項4に 記載の方法。 29.前記穿孔が、前記角質層を電気の短パルスで穿孔することにより達成され 、直径約1000μmまでの微細孔を形成する、請求項4に記載の方法。 30.前記分析物がグルコースである、請求項4、6、または19に記載の方法 。 31.前記グルコースがグルコースオキシダーゼまたは電気化学的バイオセンサ ーを用いる比色定量アッセイにより定量される、請求項30に記載の方法。 32.個体の身体の選択された領域への活性な浸透物の経皮フラックス速度を増 強する方法であって、該活性な浸透物に対する該個体の身体表面の選択された領 域の角質層の浸透性を増強させる工程を包含し、該工程が、 (a)下にある組織に重大な損傷を起こさずに微細孔を該角質層に形成し、そ してそれによって該活性な浸透物のフラックスに対する該角質層の障壁特性を減 少させる手段により、該選択された領域の該角質層を穿孔する工程;および (b)該穿孔された選択領域を、有効量の該浸透物を含む組成物と、該身体へ の該浸透物のフラックスが増強されるように接触させる工程、 を包含する、方法。 33.前記穿孔された選択領域に流体のストリーミング効果を作成するに有効な 時間および強度および周波数で音波エネルギーを適用し、それによって前記浸透 物の前記身体への経皮フラックス速度を増強する工程をさらに包含する、請求項 32に記載の方法。 34.前記音波エネルギーが、前記穿孔された選択領域に約5kHzから100MHzの 範囲で適用され、該音波エネルギーが、周波数変調、振幅変調、位相変調、およ びこれらの組合せからなる群より選択されるメンバーにより変調される、請求項 33に記載の方法。 35.前記音波エネルギーの適用とともに、前記個体の身体の選択された領域を 化学的増強剤と接触させ、該個体の身体への前記浸透物のフラックスを促進する 工程をさらに包含する、請求項34に記載の方法。 36.前記選択された領域における前記角質層を穿孔する工程が、(a)該角質 層の約1000μmまでを横切る選択された領域を、熱供給源と、該選択された領域 中の組織に結合した水および他の気化し得る物質の温度が該水および他の気化し 得る物質の沸点を超えて上昇するように接触させ、それによって該選択された領 域の角質層を除去することにより該角質層を切除する工程;(b)該角質層を、 直径約1000μmまでの微細孔を形成するように較正された微小ランセットで穿孔 する工程、(c)密接に焦点を合わせた音波エネルギーのビームを該角質層上に 焦点を合わせることにより該角質層を切除する工程;(d)流体の高圧ジェット を用いて該角質層を水動力学的に穿孔し、直径約1000μmまでの微細孔を形成す る工程、および(e)該角質層に電気の短パルスで穿孔し、直径約1000μmまでの 微細孔を形成する工程、からなる群より選択される手段により達成される、請求 項32、33、34、または35に記載の方法。 37.前記穿孔する工程が、前記角質層の約1000μmまでを横切る前記選択され た領域を、熱供給源と、該選択された領域中の組織に結合した水および他の気化 し得る物質の温度が、該水および他の気化し得る物質の沸点を超えて上昇し、そ れによって該選択された領域の角質層を除去するように接触させることにより達 成される、請求項36に記載の方法。 38.少なくとも前記選択された領域を、パルス化光供給源の発光範囲にわたっ て強い吸収を示す有効量の色素で処理する工程、および該パルス化光供給源から の一連のパルス出力を該色素上に焦点を合わせ、該色素が、該選択された領域中 の組織に結合した水および他の気化し得る物質の温度を該水および他の気化し得 る物質の沸点を超えて上昇するために該角質層に熱を伝導的に移すに十分加熱さ れる工程を包含する請求項37に記載の方法であって、該色素が熱供給源として 機能する、方法。 39.前記パルス化光供給源が、皮膚により有意に吸収されない波長で発光する 、請求項38に記載の方法。 40.前記パルス化光供給源が、約630から1550nmの範囲で発光放射するレーザ ーダイオードである、請求項39に記載の方法。 41.前記パルス化光供給源が、約700から3000nmの範囲で発光する、光学パラ メトリックス発振器で駆動されるレーザーダイオードである、請求項39に記載 の方法。 42.前記パルス化光供給源が、アークランプ、白熱電球、および発光ダイオー ドからなる群から選択されるメンバーである、請求項39に記載の方法。 43.前記角質層の障壁特性が克服された時を決定するための感知システムを提 供する工程をさらに包含する、請求項38に記載の方法。 44.前記感知システムが、前記選択された領域から反射された光を受け取りそ して発光ダイオード上に該反射された光の焦点を合わせるための光収集手段、該 焦点を合わせた光を受け取りそしてコントローラーに信号を送る発光ダイオード であって、該シグナルが該反射された光の質を示す、発光ダイオード、および該 信号を受け取りそして予め選択されたシグナルを受け取られると該パルス化光供 給源を遮断するための該発光ダイオードならびに該パルス化光供給源に接続され たコントローラーを備える、請求項43に記載の方法。 45.前記角質層の選択された領域および隣接する皮膚組織を、穿孔の前に、該 選択された領域および隣接する皮膚組織が、選択された予め冷却された定常状態 条件にあるように冷却手段で冷却する工程をさらに包含する、請求項38に記載 の方法。 46.前記冷却手段がペルチェデバイスを備える、請求項45に記載の方法。 47.前記角質層を穿孔する前に、少なくとも前記選択された領域を、前記パル ス化光供給源からの焦点の合わせていない光で、該光によって照射された該選択 された領域が滅菌されるように照射される工程をさらに包含する、請求項38に 記載の方法。 48.前記選択された領域を金属ワイヤと接触させる工程を包含する請求項37 に記載の方法であって、該ワイヤが、該選択された領域の温度が周辺の皮膚温度 から100℃を超えるまで約10〜50ms以内に上昇され、次いで該選択された領域の 温度がほぼ周辺の皮膚温度にまで約30〜50ms以内に戻るような熱供給源として機 能し、そして温度を上昇させることおよび周辺の皮膚温度に戻ることのサイクル が該角質層の障壁特性を減少させるために有効な回数繰り返す、方法。 49.前記ほぼ周辺の皮膚温度まで戻ることが、前記ワイヤを前記角質層との接 触から引き離すことにより行われる、請求項48に記載の方法。 50.前記ワイヤと前記個体の身体との間の電気的インピーダンスを前記角質層 の選択された領域および隣接皮膚組織を通して監視するための手段、および前記 切除が抵抗の減少と同時に起こるように該ワイヤの位置を進行させるための手段 であって、該ワイヤの加熱の間に該ワイヤが該角質層と接触するように該ワイヤ を進行させる、手段、を提供する工程をさらに包含する、請求項49に記載の方 法。 51.前記ワイヤを前記角質層との接触から引き離すための手段をさらに包含す る請求項50に記載の方法であって、前記鑑視手段が、該角質層の下にある表皮 層との接触に関連するインピーダンスの変化を検出し得、かつ該ワイヤを該角質 層との接触から離れるための信号を該引き離すための手段に送り得る、方法。 52.前記金属ワイヤが、オーム発熱要素により加熱される、請求項49に記載 の方法。 53.前記金属ワイヤが、高い抵抗点を有する電流ループを含み、そして該高い 抵抗点の温度が、変調された電流を該電流ループを通して通過させることにより 変調されるように形成される、請求項49に記載の方法。 54.前記金属ワイヤが、励起コイルの変調可能な交流磁場に、該励起コイルに 交流を通電することが該ワイヤを内部の抵抗損失により加熱するに十分な渦電流 を発生するように配置される、請求項49に記載の方法。 55.前記穿孔が微小ランセットで前記角質層に穿孔することにより達成され、 直径約1000μmまでの微細孔を形成する、請求項36に記載の方法。 56.前記穿孔が、密接に焦点を合わせた音波エネルギーのビームを、該角質層 上に焦点を合わせることによって前記角質層を切除することにより達成される、 請求項36に記載の方法。 57.前記穿孔が、流体の高圧ジェットを用いて水動力学的に前記角質層を穿孔 することにより達成され、直径約1000μmまでの微細孔を形成する、請求項36 に記載の方法。 58.前記穿孔が、前記角質層に電気の短パルスで穿孔することにより達成され 、直径約1000μmまでの微細孔を形成する、請求項36に記載の方法。 59.個体の身体表面の選択された領域へ入れ墨を付与する方法であって、以下 の工程: (a)下にある組織に重大な損傷を起こさずに角質層に微細孔を形成し、そし てそれによって活性な浸透物のフラックスに対する該角質層の障壁特性を減少さ せることにより、該選択された領域の角質層を穿孔する工程;および (b)該穿孔された選択領域を、有効量の入れ墨用インクを含む組成物と、該 身体への該インクのフラックスが増強されるように接触させる、工程、 を包含する、方法。 60.個体の血液から該個体の皮膚の選択された領域中の間質液への分析物の拡 散の時間的な遅滞を減少する方法であって、冷却手段を、該選択された皮膚の領 域に適用する工程を包含する、方法。 61.間質液の蒸発およびその蒸気圧を減少させる方法であって、該間質液が個 体の皮膚の角質層の選択された領域における微細孔から回収され、該選択された 皮膚の領域に冷却手段を適用する工程を包含する、方法。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52054795A | 1995-08-29 | 1995-08-29 | |
| US08/520,547 | 1995-08-29 | ||
| US804395P | 1995-10-30 | 1995-10-30 | |
| US60/008,043 | 1995-10-30 | ||
| PCT/US1996/013865 WO1997007734A1 (en) | 1995-08-29 | 1996-08-29 | Microporation of human skin for drug delivery and monitoring applications |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006038655A Division JP2006192285A (ja) | 1995-08-29 | 2006-02-15 | 薬物送達および鑑視適用のためのヒト皮膚の微細穿孔 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11511360A true JPH11511360A (ja) | 1999-10-05 |
| JP3899427B2 JP3899427B2 (ja) | 2007-03-28 |
Family
ID=26677684
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51055297A Expired - Lifetime JP3899427B2 (ja) | 1995-08-29 | 1996-08-29 | 薬物送達および鑑視適用のためのヒト皮膚の微細穿孔 |
| JP2006038655A Withdrawn JP2006192285A (ja) | 1995-08-29 | 2006-02-15 | 薬物送達および鑑視適用のためのヒト皮膚の微細穿孔 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006038655A Withdrawn JP2006192285A (ja) | 1995-08-29 | 2006-02-15 | 薬物送達および鑑視適用のためのヒト皮膚の微細穿孔 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0858285A4 (ja) |
| JP (2) | JP3899427B2 (ja) |
| CN (1) | CN1174713C (ja) |
| AU (1) | AU707065B2 (ja) |
| BR (1) | BR9610012A (ja) |
| CA (1) | CA2199002C (ja) |
| ES (1) | ES2536459T3 (ja) |
| GB (1) | GB2307414B (ja) |
| IL (1) | IL123379A (ja) |
| NO (1) | NO334437B1 (ja) |
| PT (1) | PT1563788E (ja) |
| TR (1) | TR199800347T1 (ja) |
| WO (1) | WO1997007734A1 (ja) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002257831A (ja) * | 2001-02-28 | 2002-09-11 | Kaihatsu Komonshitsu:Kk | パッチテスト用シート |
| JP2006326147A (ja) * | 2005-05-30 | 2006-12-07 | Shingo Wakamatsu | レーザー治療装置 |
| JP2007508914A (ja) * | 2003-10-24 | 2007-04-12 | アルザ・コーポレーシヨン | 経皮薬剤送達を促進するための装置及び方法 |
| JP2007510445A (ja) * | 2003-10-24 | 2007-04-26 | アルザ・コーポレーシヨン | 経皮薬剤送達促進用の前処置法及びシステム |
| WO2008059810A1 (en) * | 2006-11-14 | 2008-05-22 | Kagoshima University | Drug injecting device |
| JP2010158510A (ja) * | 1998-03-06 | 2010-07-22 | Spectrx Inc | 生物医学的適用のための光熱的構造物、およびその方法 |
| JP5407868B2 (ja) * | 2007-11-06 | 2014-02-05 | コニカミノルタ株式会社 | 微小開口形成装置およびそれを用いる体液収集システム |
| JP2015128599A (ja) * | 2005-06-17 | 2015-07-16 | 日東電工株式会社 | 浸透物デリバリーシステムおよびその使用方法 |
| JP2019526306A (ja) * | 2016-06-20 | 2019-09-19 | ユニバーシティ・オブ・ノース・テキサスUniversity of North Texas | 非モノリシックで複合的な骨材料のレーザ応用機械加工(lam) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251100B1 (en) | 1993-09-24 | 2001-06-26 | Transmedica International, Inc. | Laser assisted topical anesthetic permeation |
| EP0914178B1 (en) | 1996-06-18 | 2003-03-12 | Alza Corporation | Device for enhancing transdermal agent delivery or sampling |
| CA2259437C (en) * | 1996-07-03 | 2006-12-05 | Altea Technologies, Inc. | Multiple mechanical microporation of skin or mucosa |
| ATE231015T1 (de) * | 1996-09-17 | 2003-02-15 | Deka Products Lp | System zur medikamentenabgabe durch transport |
| US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
| US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| ES2289192T3 (es) * | 1996-12-31 | 2008-02-01 | Altea Therapeutics Corporation | Microporacion de tejido para suministro de agentes bioactivos. |
| US6527716B1 (en) | 1997-12-30 | 2003-03-04 | Altea Technologies, Inc. | Microporation of tissue for delivery of bioactive agents |
| US6027496A (en) * | 1997-03-25 | 2000-02-22 | Abbott Laboratories | Removal of stratum corneum by means of light |
| EP1017320A1 (en) | 1997-10-21 | 2000-07-12 | Townsend Engineering Company | Apparatus and method for the collection of interstitial fluids |
| US6155992A (en) * | 1997-12-02 | 2000-12-05 | Abbott Laboratories | Method and apparatus for obtaining interstitial fluid for diagnostic tests |
| US6918901B1 (en) | 1997-12-10 | 2005-07-19 | Felix Theeuwes | Device and method for enhancing transdermal agent flux |
| DE69839969D1 (de) | 1997-12-11 | 2008-10-16 | Alza Corp | Vorrichtung zur verbesserung des transdermalen flusses von medikamenten |
| JP4061022B2 (ja) * | 1997-12-11 | 2008-03-12 | アルザ・コーポレーション | 経皮輸送剤の流量促進装置 |
| CA2313698C (en) * | 1997-12-11 | 2008-04-15 | Alza Corporation | Device for enhancing transdermal agent flux |
| US6530915B1 (en) | 1998-03-06 | 2003-03-11 | Spectrx, Inc. | Photothermal structure for biomedical applications, and method therefor |
| US6173202B1 (en) * | 1998-03-06 | 2001-01-09 | Spectrx, Inc. | Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue |
| US6091975A (en) * | 1998-04-01 | 2000-07-18 | Alza Corporation | Minimally invasive detecting device |
| US6569157B1 (en) * | 1998-05-18 | 2003-05-27 | Abbott Laboratories | Removal of stratum corneum by means of light |
| US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| US7344499B1 (en) | 1998-06-10 | 2008-03-18 | Georgia Tech Research Corporation | Microneedle device for extraction and sensing of bodily fluids |
| US6077660A (en) * | 1998-06-10 | 2000-06-20 | Abbott Laboratories | Diagnostic assay requiring a small sample of biological fluid |
| EP1124607B1 (en) | 1998-07-14 | 2008-11-12 | Altea Therapeutics Corporation | Controlled removal of biological membrane by pyrotechnic charge for transmembrane transport |
| US7384396B2 (en) | 1998-07-21 | 2008-06-10 | Spectrx Inc. | System and method for continuous analyte monitoring |
| AU5004299A (en) * | 1998-07-21 | 2000-02-14 | Altea Technologies, Inc. | System and method for continuous analyte monitoring |
| IL141774A0 (en) * | 1998-09-04 | 2002-03-10 | Powderject Res Ltd | Monitoring methods using particle delivery methods |
| US6468229B1 (en) | 1998-10-20 | 2002-10-22 | Abbott Laboratories | Apparatus and method for the collection of interstitial fluids |
| US6148232A (en) | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
| US6597946B2 (en) | 1998-11-09 | 2003-07-22 | Transpharma Ltd. | Electronic card for transdermal drug delivery and analyte extraction |
| US6708060B1 (en) | 1998-11-09 | 2004-03-16 | Transpharma Ltd. | Handheld apparatus and method for transdermal drug delivery and analyte extraction |
| US6611706B2 (en) | 1998-11-09 | 2003-08-26 | Transpharma Ltd. | Monopolar and bipolar current application for transdermal drug delivery and analyte extraction |
| US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
| US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
| ATE324922T1 (de) * | 1999-06-08 | 2006-06-15 | Altea Therapeutics Corp | Vorrichtung zur mikroporation eines biologischen gewebes mittels einer filmgewebe schnittstellenvorrichtung und verfahren |
| US20030078499A1 (en) | 1999-08-12 | 2003-04-24 | Eppstein Jonathan A. | Microporation of tissue for delivery of bioactive agents |
| US6355054B1 (en) * | 1999-11-05 | 2002-03-12 | Ceramoptec Industries, Inc. | Laser system for improved transbarrier therapeutic radiation delivery |
| DE19963034A1 (de) | 1999-12-24 | 2001-06-28 | Roche Diagnostics Gmbh | System zur verbesserten Bestimmung des Glukosespiegels anhand von Messungen in interstitieller Flüssigkeit |
| IL136008A0 (en) | 2000-05-07 | 2001-05-20 | Elecsys Ltd | Electrically-mediated transdermal drug injection |
| US6706032B2 (en) | 2000-06-08 | 2004-03-16 | Massachusetts Institute Of Technology | Localized molecular and ionic transport to and from tissues |
| US7597692B2 (en) | 2000-06-08 | 2009-10-06 | Massachusetts Institute Of Technology | Microscission processes and procedures |
| AUPR044000A0 (en) * | 2000-09-28 | 2000-10-26 | Norwood Abbey Ltd | Diagnostic device |
| US6537243B1 (en) | 2000-10-12 | 2003-03-25 | Abbott Laboratories | Device and method for obtaining interstitial fluid from a patient for diagnostic tests |
| US6882884B1 (en) | 2000-10-13 | 2005-04-19 | Soundskin, L.L.C. | Process for the stimulation of production of extracellular dermal proteins in human tissue |
| US6733493B2 (en) * | 2000-11-16 | 2004-05-11 | Innotech Usa, Inc. | Laser skin perforator |
| US9302903B2 (en) | 2000-12-14 | 2016-04-05 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
| WO2002050584A2 (en) | 2000-12-21 | 2002-06-27 | Biovalve Technologies, Inc. | Microneedle array systems |
| ES2310201T3 (es) | 2001-02-13 | 2009-01-01 | Government Of The United States Of America, As Represented By The Secretary Of The Army | Vacuna para inmunizacion transcutanea contra la diarrea de los viajeros. |
| US6790179B2 (en) | 2001-08-01 | 2004-09-14 | Johnson & Johnson Consumer Companies, Inc. | Method of examining and diagnosing skin health |
| US6855117B2 (en) | 2001-08-01 | 2005-02-15 | Johnson & Johnson Consumer Companies, Inc. | Method of treating the skin of a subject |
| US6840910B2 (en) | 2001-08-01 | 2005-01-11 | Johnson & Johnson Consumer Companies, Inc. | Method of distributing skin care products |
| WO2003024507A2 (en) | 2001-09-19 | 2003-03-27 | Biovalve Technologies, Inc. | Microneedles, microneedle arrays, and systems and methods relating to same |
| AU2002330083A1 (en) | 2001-09-21 | 2003-04-01 | Biovalve Technologies, Inc. | Gas pressure actuated microneedle arrays, and systems and methods relating to same |
| AU2002353444A1 (en) | 2001-11-07 | 2003-05-19 | Transpharma Medical Ltd. | Integrated transdermal drug delivery system |
| CA2478822C (en) | 2002-03-11 | 2016-07-12 | Passport Technologies, Inc. | Transdermal drug delivery patch system, method of making same and method of using same |
| US9918665B2 (en) | 2002-03-11 | 2018-03-20 | Nitto Denko Corporation | Transdermal porator and patch system and method for using same |
| WO2003089043A2 (en) | 2002-04-19 | 2003-10-30 | Transpharma Medical Ltd. | Handheld transdermal drug delivery and analyte extraction |
| US7662404B2 (en) | 2002-10-31 | 2010-02-16 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides |
| US7383084B2 (en) | 2002-10-31 | 2008-06-03 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| US8133505B2 (en) | 2002-10-31 | 2012-03-13 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| IL152574A (en) | 2002-10-31 | 2009-09-22 | Transpharma Medical Ltd | A system for passing through the skin of dry items or dried medicines |
| IL152575A (en) | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| IL152573A (en) | 2002-10-31 | 2009-11-18 | Transpharma Medical Ltd | A system for the transmission through the skin of a medical preparation against vomiting and nausea |
| US7258673B2 (en) | 2003-06-06 | 2007-08-21 | Lifescan, Inc | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein |
| US8016811B2 (en) | 2003-10-24 | 2011-09-13 | Altea Therapeutics Corporation | Method for transdermal delivery of permeant substances |
| CA2584800A1 (en) | 2004-10-21 | 2006-05-04 | Bayer Healthcare Llc | Method of determining the concentration of an analyte in a body fluid and system therefor |
| JP5011936B2 (ja) * | 2006-10-11 | 2012-08-29 | パナソニック株式会社 | 血液検査装置 |
| JP5011935B2 (ja) * | 2006-10-11 | 2012-08-29 | パナソニック株式会社 | 血液検査装置 |
| RU2328739C1 (ru) * | 2007-02-26 | 2008-07-10 | Айрат Анварович Халиков | Способ определения целостности клеточных мембран биологической ткани трупа |
| JP2010525881A (ja) * | 2007-04-27 | 2010-07-29 | エコー セラピューティクス, インコーポレイテッド | 被検体の検知または経皮的薬物送達のための皮膚透過装置 |
| CA2704740C (en) | 2007-10-09 | 2016-05-17 | Transpharma Ltd. | Magnetic patch coupling |
| CA2696227A1 (en) | 2007-10-17 | 2009-04-23 | Transpharma Medical Ltd. | Dissolution rate verification |
| JP2011505899A (ja) | 2007-12-05 | 2011-03-03 | シネロン メディカル リミテッド | 使い捨て可能な電磁気エネルギーアプリケータ及びそれを使用する方法 |
| GB0811856D0 (en) | 2008-06-27 | 2008-07-30 | Ucl Business Plc | Magnetic microbubbles, methods of preparing them and their uses |
| US8606366B2 (en) | 2009-02-18 | 2013-12-10 | Syneron Medical Ltd. | Skin treatment apparatus for personal use and method for using same |
| US20100256466A1 (en) * | 2009-04-02 | 2010-10-07 | Avraham Shekalim | Metabolite Management System |
| JP5774001B2 (ja) | 2009-07-27 | 2015-09-02 | ノヴォクセル リミテッド | 組織焼灼のための方法および装置 |
| PT105635B (pt) | 2011-04-19 | 2014-04-11 | Univ De Coimbra | Dispositivo para a administração eficiente de compostos na pele ou barreiras biológicas, ou através dessas, usando filmes finos absorventes de luz |
| CN105939684B (zh) | 2013-12-18 | 2020-06-09 | 诺服塞尔有限公司 | 汽化组织的设备及方法 |
| WO2016042547A1 (en) * | 2014-09-15 | 2016-03-24 | Novoxel Ltd. | Methods and devices for thermal surgical vaporization and incision of tissue |
| PL3193761T3 (pl) | 2014-09-15 | 2021-10-18 | Novoxel Ltd. | Sposoby wytwarzania urządzeń do cieplnego parowania i uciskania tkanki |
| KR20170134478A (ko) * | 2015-03-03 | 2017-12-06 | 가이디드 테라피 시스템스, 엘.엘.씨. | 인조 마이크로채널을 통해 불투막 또는 반투막을 통과하여 물질을 이동하기 위한 방법 및 시스템 |
| JP6876045B2 (ja) * | 2015-12-15 | 2021-05-26 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | 表面処理装置及び方法 |
| US20190029654A1 (en) * | 2016-01-15 | 2019-01-31 | University Of Cincinnati | Advanced electroporation devices and methods for analyte access in biofluids |
| FI127811B (en) * | 2016-11-21 | 2019-03-15 | Helsingin Yliopisto | Device for sampling one or more analytes |
| HUE069886T2 (hu) * | 2017-02-14 | 2025-04-28 | Hoffmann La Roche | Számítógéppel megvalósított eljárás és hordozható eszköz testfolyadék glükózszintjére vonatkozó glükózmonitorozási adatok elemzésére, valamint számítógéppel olvasható tartós adathordozó |
| US11441994B2 (en) * | 2017-07-27 | 2022-09-13 | Tata Consultancy Services Limited | Method and system for in-silico design of skin electroporation |
| WO2019025610A1 (en) * | 2017-08-03 | 2019-02-07 | Fibrotx Oü | LATERAL FLOW DOSING AND DEVICE FOR SKIN CARE APPLICATION |
| CN109157280A (zh) * | 2018-08-10 | 2019-01-08 | 重庆大学 | 不可逆电穿孔组织消融效果动态实时评估设备 |
| DK3804648T3 (da) * | 2018-08-23 | 2022-04-11 | Novocure Gmbh | Anvendelse af elektriske vekseltrømsfelter til forøgelse af permeabilitet af blodhjernebarrieren |
| CN114375181B (zh) * | 2019-06-28 | 2025-10-31 | 帕斯帕特技术有限公司 | 用于控制向细丝装置递送能量的方法和系统 |
| TWI729670B (zh) * | 2019-08-02 | 2021-06-01 | 華廣生技股份有限公司 | 生物感測器之植入裝置 |
| CN110613893A (zh) * | 2019-10-31 | 2019-12-27 | 南京工业职业技术学院 | 一种新型励磁线圈 |
| CN111693434B (zh) * | 2020-06-19 | 2024-01-19 | 中建路桥集团有限公司 | 一种测试混凝土抗渗性能的实验装置 |
| CN114504373A (zh) * | 2020-11-16 | 2022-05-17 | 澳美力科技(成都)有限公司 | 一种新型射频变频美容仪 |
| CN112957124B (zh) * | 2021-01-30 | 2023-08-22 | 南京理工大学 | 一种能量靶向调控的离体激光生物组织焊接缝合方法 |
| CN115670642A (zh) * | 2021-05-20 | 2023-02-03 | 黄虹凤 | 保证高精度和高速度的激光切线装置 |
| CN114343839B (zh) * | 2021-12-30 | 2024-07-23 | 德州环球之光医疗科技股份有限公司 | 一种基于可调的螺旋线型激光光斑的治疗图形转换方法 |
| CN116999687B (zh) * | 2023-07-19 | 2024-11-12 | 河南翔宇医疗设备股份有限公司 | 一种超声渗透仪以及超声渗透仪输出参数设置装置、介质 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775361A (en) * | 1986-04-10 | 1988-10-04 | The General Hospital Corporation | Controlled removal of human stratum corneum by pulsed laser to enhance percutaneous transport |
| US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
| EP0398960B1 (en) * | 1988-01-21 | 1995-12-06 | Massachusetts Institute Of Technology | Transport of molecules across tissue using electroporation |
| US5139023A (en) | 1989-06-02 | 1992-08-18 | Theratech Inc. | Apparatus and method for noninvasive blood glucose monitoring |
| US5016615A (en) * | 1990-02-20 | 1991-05-21 | Riverside Research Institute | Local application of medication with ultrasound |
| US5115805A (en) * | 1990-02-23 | 1992-05-26 | Cygnus Therapeutic Systems | Ultrasound-enhanced delivery of materials into and through the skin |
| GB9014307D0 (en) * | 1990-06-27 | 1990-08-15 | Scient Generics Ltd | Method of treatment and compositions therefor |
| JP3189337B2 (ja) * | 1991-11-08 | 2001-07-16 | 日本電気株式会社 | 皮膚角層の除去器具および除去方法 |
| US5344418A (en) * | 1991-12-12 | 1994-09-06 | Shahriar Ghaffari | Optical system for treatment of vascular lesions |
| US5165418B1 (en) | 1992-03-02 | 1999-12-14 | Nikola I Tankovich | Blood sampling device and method using a laser |
| US5246437A (en) * | 1992-04-10 | 1993-09-21 | Abela George S | Cell treatment apparatus and method |
| US5643252A (en) * | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
| US5279552A (en) * | 1993-01-11 | 1994-01-18 | Anton Magnet | Intradermal injection device |
| US5267985A (en) * | 1993-02-11 | 1993-12-07 | Trancell, Inc. | Drug delivery by multiple frequency phonophoresis |
| US5582184A (en) * | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
| US5445611A (en) * | 1993-12-08 | 1995-08-29 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal delivery with ultrasound and chemical enhancers |
| US5458140A (en) | 1993-11-15 | 1995-10-17 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers |
| DE69624668T2 (de) * | 1995-07-25 | 2003-08-28 | Massachusetts Institute Of Technology, Cambridge | Verbesserter transdermaler transport unter verwendung von ultraschall |
-
1996
- 1996-08-29 AU AU68631/96A patent/AU707065B2/en not_active Expired
- 1996-08-29 IL IL12337996A patent/IL123379A/en not_active IP Right Cessation
- 1996-08-29 GB GB9702766A patent/GB2307414B/en not_active Expired - Lifetime
- 1996-08-29 EP EP96929098A patent/EP0858285A4/en not_active Withdrawn
- 1996-08-29 BR BR9610012-5A patent/BR9610012A/pt not_active Application Discontinuation
- 1996-08-29 CA CA002199002A patent/CA2199002C/en not_active Expired - Lifetime
- 1996-08-29 JP JP51055297A patent/JP3899427B2/ja not_active Expired - Lifetime
- 1996-08-29 ES ES05011002.2T patent/ES2536459T3/es not_active Expired - Lifetime
- 1996-08-29 WO PCT/US1996/013865 patent/WO1997007734A1/en not_active Ceased
- 1996-08-29 CN CNB961966718A patent/CN1174713C/zh not_active Expired - Lifetime
- 1996-08-29 TR TR1998/00347T patent/TR199800347T1/xx unknown
- 1996-08-29 PT PT50110022T patent/PT1563788E/pt unknown
-
1998
- 1998-02-27 NO NO19980878A patent/NO334437B1/no not_active IP Right Cessation
-
2006
- 2006-02-15 JP JP2006038655A patent/JP2006192285A/ja not_active Withdrawn
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010158510A (ja) * | 1998-03-06 | 2010-07-22 | Spectrx Inc | 生物医学的適用のための光熱的構造物、およびその方法 |
| JP2002257831A (ja) * | 2001-02-28 | 2002-09-11 | Kaihatsu Komonshitsu:Kk | パッチテスト用シート |
| JP2007508914A (ja) * | 2003-10-24 | 2007-04-12 | アルザ・コーポレーシヨン | 経皮薬剤送達を促進するための装置及び方法 |
| JP2007510445A (ja) * | 2003-10-24 | 2007-04-26 | アルザ・コーポレーシヨン | 経皮薬剤送達促進用の前処置法及びシステム |
| JP2006326147A (ja) * | 2005-05-30 | 2006-12-07 | Shingo Wakamatsu | レーザー治療装置 |
| JP2015128599A (ja) * | 2005-06-17 | 2015-07-16 | 日東電工株式会社 | 浸透物デリバリーシステムおよびその使用方法 |
| WO2008059810A1 (en) * | 2006-11-14 | 2008-05-22 | Kagoshima University | Drug injecting device |
| JPWO2008059810A1 (ja) * | 2006-11-14 | 2010-03-04 | 国立大学法人 鹿児島大学 | 薬物注入装置 |
| JP4706069B2 (ja) * | 2006-11-14 | 2011-06-22 | 国立大学法人 鹿児島大学 | 薬物注入装置 |
| US8010188B2 (en) | 2006-11-14 | 2011-08-30 | Kagoshima University | Drug injecting device |
| JP5407868B2 (ja) * | 2007-11-06 | 2014-02-05 | コニカミノルタ株式会社 | 微小開口形成装置およびそれを用いる体液収集システム |
| JP2019526306A (ja) * | 2016-06-20 | 2019-09-19 | ユニバーシティ・オブ・ノース・テキサスUniversity of North Texas | 非モノリシックで複合的な骨材料のレーザ応用機械加工(lam) |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006192285A (ja) | 2006-07-27 |
| CA2199002A1 (en) | 1997-03-01 |
| PT1563788E (pt) | 2015-06-02 |
| CA2199002C (en) | 1999-02-23 |
| GB2307414A (en) | 1997-05-28 |
| HK1009321A1 (en) | 1999-05-28 |
| CN1195276A (zh) | 1998-10-07 |
| TR199800347T1 (xx) | 1998-05-21 |
| AU6863196A (en) | 1997-03-19 |
| IL123379A (en) | 2002-04-21 |
| WO1997007734A1 (en) | 1997-03-06 |
| BR9610012A (pt) | 1999-12-21 |
| GB9702766D0 (en) | 1997-04-02 |
| JP3899427B2 (ja) | 2007-03-28 |
| EP0858285A4 (en) | 2000-05-17 |
| GB2307414B (en) | 1998-03-11 |
| ES2536459T3 (es) | 2015-05-25 |
| AU707065B2 (en) | 1999-07-01 |
| NO980878D0 (no) | 1998-02-27 |
| NO980878L (no) | 1998-04-27 |
| IL123379A0 (en) | 1998-09-24 |
| CN1174713C (zh) | 2004-11-10 |
| EP0858285A1 (en) | 1998-08-19 |
| NO334437B1 (no) | 2014-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3899427B2 (ja) | 薬物送達および鑑視適用のためのヒト皮膚の微細穿孔 | |
| US6142939A (en) | Microporation of human skin for drug delivery and monitoring applications | |
| JP5657040B2 (ja) | 生物体へ浸透性物質を送達するための、または、生物体から分析物を抽出するための装置 | |
| US6527716B1 (en) | Microporation of tissue for delivery of bioactive agents | |
| US7758561B2 (en) | Microporation of tissue for delivery of bioactive agents | |
| US6419642B1 (en) | Irradiation enhanced permeation and delivery | |
| US20020169394A1 (en) | Integrated tissue poration, fluid harvesting and analysis device, and method therefor | |
| CA2329167C (en) | Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue | |
| US20010050083A1 (en) | Irradiation enhanced permeation and delivery | |
| EP1563788B1 (en) | Microporation of human skin for drug delivery and monitoring applications | |
| RU2209031C2 (ru) | Формирование микропор в коже человека для доставки лекарственных препаратов и мониторинга | |
| WO2002026148A1 (en) | Irradiation enhanced permeation and collection | |
| WO2002026149A1 (en) | Irradiation enhanced permeation and delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050816 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051114 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060404 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060703 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060821 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061002 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061121 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20061212 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20061127 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110112 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120112 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130112 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |